Back to top
more

TELESIS BIO (TBIO)

(Delayed Data from NSDQ)

$0.32 USD

0.32
26,223

0.00 (-0.93%)

Updated Apr 26, 2024 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sanofi (SNY) Gets FDA Approval for Sarclisa Label Expansion

by Zacks Equity Research

Sanofi's (SNY) Sarclisa gets FDA approval to treat multiple myeloma patients who have received one to three prior lines of therapy in combination with Kyprolis and dexamethasone.

Translate (TBIO) Down on Unsatisfactory CF Drug Study Results

by Zacks Equity Research

Translate Bio (TBIO) announces data from second interim analysis of phase I/II study evaluating MRT5005 in patients with cystic fibrosis. The candidate fails to improve lung function in patients.

The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio

Biotech Stock Roundup: REGN's Cancer Drug Positive, COVID-19 Updates From NVAX & More

by Zacks Equity Research

The biotech sector was in focus last week with vaccine and antibody updates from quite a few companies like Novavax (NVAX) and Vir (VIR), among others.

Sanofi (SNY)/Translate Bio COVID-19 Vaccine in Clinical Stage

by Zacks Equity Research

The phase I/II clinical study on Sanofi (SNY)/Translate Bio's (TBIO) COVID-19 vaccine candidate will assess its safety, immune response and reactogenicity.

Translate Bio, Inc. (TBIO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Translate Bio, Inc. (TBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sanofi (SNY) Q4 Earnings & Sales Miss, 2021 EPS View Bright

by Zacks Equity Research

Sanofi's (SNY) Q4 earnings and sales miss estimates. Dupixent drives sales growth in the quarter

6 Biotech/Drug Stocks Up Manifold in 2020 Thanks to COVID-19

by Zacks Equity Research

We discuss six biotech/drug stocks, NVAX, VXRT, MRNA, TBIO, INO and BNTX that have more than doubled in 2020 on the back of their progress in coronavirus vaccine development.

The Zacks Analyst Blog Highlights: INO, NVAX, TBIO and VXRT

by Zacks Equity Research

The Zacks Analyst Blog Highlights: INO, NVAX, TBIO and VXRT

Indrajit Bandyopadhyay headshot

4 Biotechs Likely to Gain on Coronavirus Vaccine Efforts

by Indrajit Bandyopadhyay

In the race to develop a coronavirus vaccine, Pfizer and its partner BioNTech have a lead, closely followed by Moderna. However, four other biotechs, NVAX, TBIO, INO and VXRT, still hold potential to gain from their vaccine development efforts.

Sanofi's (SNY) Meningitis Vaccine MenQuadfi Wins EU Approval

by Zacks Equity Research

The European Commission nods to Sanofi's (SNY) MenQuadfi, a meningococcal vaccine for individuals, aged 12 months and older.

Benjamin Rains headshot

Find Strong Stocks with this First Profit Screener

by Benjamin Rains

Let's use our 'First Profit' screener to help find stocks that investors might want to consider buying after they posted positive earnings for the first time ever, or for some time...

Sanofi's (SNY) Q3 Earnings & Sales Miss, 2020 View Raised

by Zacks Equity Research

Sanofi's (SNY) earnings and sales miss estimates. It raises its earnings growth expectations for the year.

Sanofi's mRNA Vaccine for Coronavirus to Enter Clinical Stage

by Zacks Equity Research

Sanofi (SNY) and Translate Bio select coronavirus vaccine candidate MRT5500 for clinical development, based on its promising pre-clinical data. A clinical study is anticipated by this year-end.

Sanofi/Glaxo to Supply 70M Coronavirus Vaccine Doses in Canada

by Zacks Equity Research

Sanofi's (SNY) recombinant protein-based technology is being combined with Glaxo's pandemic adjuvant technology to develop an adjuvanted COVID-19 vaccine.

Sanofi/Glaxo to Supply 300M Coronavirus Vaccine Doses in EU

by Zacks Equity Research

Sanofi (SNY) recombinant protein-based technology is being combined with Glaxo's (GSK) pandemic adjuvant technology to develop an adjuvanted COVID-19 vaccine.

What's in Store for Avenue Therapeutics (ATXI) in Q2 Earnings?

by Zacks Equity Research

Avenue Therapeutics' (ATXI) sole pipeline candidate, tramadol, is under review. With lower clinical activities, operating expenses are likely to have declined during the second quarter.

What Awaits Selecta Biosciences (SELB) This Earnings Season?

by Zacks Equity Research

In the absence of any marketed drugs, investor focus is likely to be on Selecta Biosciences' (SELB) lead pipeline candidate, SEL-212 on the second-quarter conference call.

Aldeyra (ALDX) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Aldeyra's (ALDX) pipeline progress will be in focus when it reports Q2 results later in the week.

CytoDyn (CYDY) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

CytoDyn's progress on its lead candidate, leronlimab, will be in focus when it reports Q4 results.

Actinium (ATNM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Actinium's (ATNM) lead candidate, Iomab-B, being evaluated for acute myeloid leukemia will be in focus when the company reports second-quarter earnings.

Onconova (ONTX) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will focus on pipeline updates when Onconova (ONTX) reports Q2 results.

Is a Beat in the Cards for Bristol-Myers' (BMY) Q2 Earnings?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2020 results.

Teva (TEVA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Teva's (TEVA) second-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products

Has Translate Bio (TBIO) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (TBIO) Outperforming Other Medical Stocks This Year?